Chronic Kidney Disease - Pipeline Insight, 2025

DelveInsight's, "Chronic Kidney Disease - Pipeline Insight, 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Chronic Kidney Disease: Understanding

Chronic Kidney Disease: Overview

Chronic Kidney Disease (CKD) is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

Patients feel unwell or have symptoms with mild-to-moderate chronic kidney disease that is, stages 1 to 3. Chronic kidney disease is usually diagnosed by the eGFR test before any symptoms develop. Symptoms tend to develop when chronic kidney disease becomes severe (stage 4) or worse. The symptoms at first tend to be vague and nonspecific, such as feeling tired, having less energy than usual and just not feeling well.

Chronic kidney disease is caused by progressive decline in all kidney functions, leading to kidney damage. During this time, there is modulation and adaptation in the still-functional glomeruli, which keeps the kidneys functioning normally for as long as possible. The remaining glomeruli, therefore, experience a rise in pressure through hyper filtration. The release of various cytokines and growth factors leads to hypertrophy and hyperplasia. At the same time, the function of the glomeruli suffers due to the excessive demands on them, leading to increased permeability and proteinuria. Increased protein concentrations in the proximal tube system are direct nephrotoxins and can further impair kidney function.

CKD normally has no symptoms until the kidneys are severely damaged. Timely and routine testing is the only way to find out how well the kidney is functioning. The majority of people are diagnosed using blood and urine. These tests may be performed as part of a standard check-up or if you are at risk of developing CKD. The tests check for abnormally high levels of particular compounds such as GFR and protein in the blood and urine, which indicate that your kidneys aren't functioning properly. The results value indicates the severity of kidney disease, with a larger value signifying more severe CKD.

Chronic kidney disease (CKD) has no cure, but treatment can help relieve symptoms and prevent it from worsening. While the damage to your kidneys cannot be reversed, precautions to maintain them as healthy for as long as possible. The treatment will depend on the stage of CKD. Once detected with CKD, the following treatment and management options can be addressed. Medicine can help control many of the problems that cause the condition and the complications that can happen as a result of it. Since, CKD can be affected by a group of diseases which include diabetes, high blood pressure, high cholesterol, anemia and many more. Therefore, the proper medication can be prescribed by the doctor to better manage the associated problems caused by CKD. Kidney transplant recipients are a subset of patients with chronic kidney disease (CKD) that remain at high risk for progression to dialysis and mortality. Recent advances in immunosuppression have only partially improved long-term graft and patient survival.

"Chronic Kidney Disease- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Kidney Disease.

Chronic Kidney Disease Emerging Drugs Chapters

This segment of the Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Kidney Disease Emerging Drugs

• Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with CKD.

• Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

• BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of a sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

• PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

• RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

Chronic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Kidney Disease
• There are approx. 75+ key companies which are developing the therapies for Chronic Kidney Disease. The companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca and Novo Nordisk.
• Phases

DelveInsight's report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Kidney Disease drugs.

Chronic Kidney Disease Report Insights

• Chronic Kidney Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Kidney Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Kidney Disease drugs?
• How many Chronic Kidney Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Kidney Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Eli Lilly and Company
• Shandong Suncadia Medicine
• Boehringer Ingelheim
• AdAlta
• Alebund Pharmaceuticals
• SCOHIA PHARMA
• DiaMedica Therapeutics
• Roche
• MC2 Therapeutics
• Allena Pharmaceuticals
• Regulus Therapeutics
• UnicoCell Biomed
• Regeneron Pharmaceuticals

Key Products

• Baxdrostat
• Tirzepatide
• HRS-1780
• BI-685509
• AD-214
• AP 304
• SCO-792
• DM199
• Pirfenidone
• Verinurad
• MC2-25
• AZD9977
• ALLN-346
• RGLS8429
• ELIXCYTE